Methods of determining a surgical margin and methods of use thereof
Provided herein are methods of determining a surgical margin and the site and size of a tissue to be resected from a subject, and methods of use thereof.
1. A method of identifying a surgical margin for resection of a tissue in a subject, the method comprising:
(a) contacting a tissue sample obtained from the subject with a plurality of analyte capture agents, wherein an analyte capture agent of the plurality comprises:
(I) an analyte binding moiety that binds to a protein,
(II) an analyte binding moiety barcode, and
(III) an analyte capture sequence;
(b) contacting the tissue sample obtained from the subject with a substrate comprising a plurality of capture probes affixed to the substrate, wherein a capture probe of the plurality comprises (i) a capture domain that hybridizes to the analyte capture sequence and (ii) a spatial barcode;
(c) permeabilizing the tissue sample and hybridizing the analyte capture sequence of the first analyte capture agent from the tissue sample to the capture probe capture domain,
(d) hybridizing a second analyte from the tissue sample to a second capture probe on the substrate, wherein the second capture probe comprises (i) a capture domain that hybridizes to a second analyte and (ii) a second spatial barcode;
(e) determining (i) all or a portion of the first analyte capture sequence and the analyte binding moiety barcode, or complements thereof, (ii) the spatial barcode or a complement thereof, (iii) all or a portion of the second analyte, or a complement thereof, and (iv) the second spatial barcode associated with the second analyte, or a complement thereof, and using (i), (ii), (iii), and (iv) to identify the presence of the analytes in the tissue sample, and
(f) identifying the surgical margin for resection of the tissue in the subject based on the locations of the analytes in the tissue sample.
2. The method of claim 1 , wherein the tissue sample is a cancerous tissue from a sarcoma, a carcinoma, a glioma, a breast cancer, a brain cancer, a lung cancer, a colon cancer, a reproductive tissue cancer, a kidney cancer, a liver cancer, a melanoma, an ovarian cancer, or a uterine cancer.
3. The method of claim 2 , wherein the breast cancer is ductal carcinoma.
4. The method of claim 1 , wherein the second analyte is mRNA or DNA.
5. The method of claim 1 , wherein the determining comprises sequencing the analyte capture sequence, the second analyte, the spatial barcode, and the second spatial barcode.
6. The method of claim 1 , wherein the determining comprises fluorescence.
7. The method of claim 6 , wherein the fluorescence is in situ fluorescence.
8. The method of claim 1 , wherein the tissue for resection is a tumor, an infected tissue, necrotic tissue or diseased tissue.
9. The method of claim 8 , wherein the infected tissue is infected by a bacterium , a virus, a fungus, a parasite and/or protozoa.
10. The method of claim 1 , wherein the capture probe and/or the second capture probe further comprise one or more functional domains, a unique molecular identifier, a cleavage domain, or any combination thereof.
11. The method of claim 1 , further comprising determining the size and site of the tissue sample to be resected.
12. The method of claim 1 , wherein the resection reduces risk of re-excision of additional tissue from the subject.
13. The method of claim 1 , wherein the method results in (i) a reduced rate of re-excision of the tissue in the subject, and/or (ii) a reduced rate of recurrence of tissue abnormality in the subject.
14. The method of claim 1 , further comprising administering a treatment of surgery to the subject after step (f).
15. A method of identifying a surgical margin for resection of a tissue in a subject, the method comprising:
(a) contacting a tissue sample obtained from the subject to a first substrate,
(b) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the tissue sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein each capture probe comprises a spatial barcode and a capture domain,
(c) permeabilizing the tissue sample and hybridizing a first analyte and a second analyte from the tissue sample to a second capture domain of a second capture probe comprising a second spatial barcode,
(d) determining (i) all or a part of a nucleic acid sequence corresponding to the first analyte, or a complement thereof, (ii) the spatial barcode associated with the first analyte, or a complement thereof, (iii) all or a part of a nucleic acid sequence corresponding to the second analyte, or a complement thereof, and (iv) the second spatial barcode associated with the second analyte, or a complement thereof, and using the determined nucleic acid sequences of (i), (ii), (iii) and (iv) to identify the presence of the first and second analyte at locations in the tissue, and
(e) identifying the surgical margin for resection of the tissue in the subject based on the location of the first and second analyte.
16. The method of claim 15 , wherein the tissue in the subject is resected based on the identified location of the surgical margin.
17. The method of claim 15 , wherein the tissue is from a sarcoma, a carcinoma, a glioma, a breast cancer, a brain cancer, a lung cancer, a colon cancer, a reproductive tissue cancer, a kidney cancer, a liver cancer, a melanoma, an ovarian cancer, or a uterine cancer.
18. The method of claim 17 , wherein the breast cancer is ductal carcinoma.
19. The method of claim 15 , wherein the first analyte is a protein and the second analyte is mRNA or DNA.
20. The method of claim 15 , wherein the determining comprises sequencing the nucleic acid sequences of the first and second analytes, the spatial barcode, and the second spatial barcode.
21. The method of claim 15 , wherein the determining comprises fluorescence.
22. The method of claim 21 , wherein the fluorescence is in situ fluorescence.
23. The method of claim 15 , wherein the resected tissue comprises a tumor, an infected tissue, necrotic tissue or diseased tissue.
24. The method of claim 23 , wherein the infected tissue is infected by a bacterium , a virus, a fungus, a parasite and/or protozoa.
25. The method of claim 15 , wherein the capture probes further comprise one or more functional domains, a unique molecular identifier, a cleavage domain, or any combination thereof.
26. The method of claim 15 , further comprising determining the size and site of the tissue to be resected.
27. The method of claim 15 , wherein the resection reduces risk of re-excision of additional tissue from the subject.
28. The method of claim 15 , wherein the method results in (i) a reduced rate of re-excision of the tissue, and/or (ii) a reduced rate of recurrence of tissue abnormality in the subject.
29. The method of claim 15 , further comprising administering a treatment of surgery to the subject after step (e).
30. The method of claim 1 , wherein the tissue sample was previously stained by hematoxylin and eosin, immunohistochemistry, and/or immunofluorescence.